Another Wyeth Drug Is Delayed!
Wyeth and its development partner, Tarrytown NY-based Progenics Pharmaceuticals Inc, said on Thursday that U.S. regulators have delayed a review of their experimental drug to treat opioid-induced constipation in order to further review certain safety data.
The U.S. Food and Drug Administration asked for the results of a recently completed study of the drug, methylnaltrexone, on QT prolongation, a disorder of the heart's electrical system. The companies said the study submitted to the FDA examined the effect of intravenous methylnaltrexone, which is being developed for post-operative ileus, a dysfunction of the gastrointestinal tract following surgery.
Both companies hope that FDA will review the application by the end of April, three months later than expected. I suspect that the old adage “If at first you don’t succeed, try, try, and try again” may be the new mantra at Wyeth these days!
Until next time….
Good Luck and Good Job Hunting!!!!!!!!!!
